Terms: = Prostate cancer AND CDH1, uvomorulin, 999, P12830, ENSG00000039068, CDHE, Arc-1, UVO, LCAM, CD324, ECAD AND Prognosis
23 results:
1. [Research on the anti-tumor effects of CRYAB in prostate cancer].
Zhang CL; Hu Y; Wang DX; Yang Q; Chang DH
Zhonghua Nan Ke Xue; 2023 Jul; 29(7):579-286. PubMed ID: 38619403
[TBL] [Abstract] [Full Text] [Related]
2. Six-transmembrane epithelial antigen of prostate 3 (STEAP3) is a potential prognostic biomarker in clear cell renal cell carcinoma that correlates with M2 macrophage infiltration and epithelial-mesenchymal.
Wei H; Li Z; Zhao Y; Zhu S; Wen S; Quan C
Cancer Rep (Hoboken); 2023 Aug; 6(8):e1824. PubMed ID: 37344930
[TBL] [Abstract] [Full Text] [Related]
3. The Transcriptomic Profiles of
Olczak M; Orzechowska MJ; Bednarek AK; Lipiński M
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176106
[TBL] [Abstract] [Full Text] [Related]
4. Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer.
Genitsch V; Kollár A; Vandekerkhove G; Blarer J; Furrer M; Annala M; Herberts C; Pycha A; de Jong JJ; Liu Y; Krentel F; Davicioni E; Gibb EA; Kruithof-de Julio M; Wyatt AW; Seiler R
Urol Oncol; 2019 Nov; 37(11):826-836. PubMed ID: 31585777
[TBL] [Abstract] [Full Text] [Related]
5. Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer.
Genitsch V; Kollár A; Vandekerkhove G; Blarer J; Furrer M; Annala M; Herberts C; Pycha A; de Jong JJ; Liu Y; Krentel F; Davicioni E; Gibb EA; Kruithof-de Julio M; Wyatt AW; Seiler R
Urol Oncol; 2019 Sep; 37(9):573.e19-573.e29. PubMed ID: 31358384
[TBL] [Abstract] [Full Text] [Related]
6. E-Cadherin Represses Anchorage-Independent Growth in Sarcomas through Both Signaling and Mechanical Mechanisms.
Jolly MK; Ware KE; Xu S; Gilja S; Shetler S; Yang Y; Wang X; Austin RG; Runyambo D; Hish AJ; Bartholf DeWitt S; George JT; Kreulen RT; Boss MK; Lazarides AL; Kerr DL; Gerber DG; Sivaraj D; Armstrong AJ; Dewhirst MW; Eward WC; Levine H; Somarelli JA
Mol Cancer Res; 2019 Jun; 17(6):1391-1402. PubMed ID: 30862685
[TBL] [Abstract] [Full Text] [Related]
7. STEAP1 Inhibits Breast cancer Metastasis and Is Associated With Epithelial-Mesenchymal Transition Procession.
Xie J; Yang Y; Sun J; Jiao Z; Zhang H; Chen J
Clin Breast Cancer; 2019 Feb; 19(1):e195-e207. PubMed ID: 30253922
[TBL] [Abstract] [Full Text] [Related]
8. The p21-activated kinase 4-Slug transcription factor axis promotes epithelial-mesenchymal transition and worsens prognosis in prostate cancer.
Park JJ; Park MH; Oh EH; Soung NK; Lee SJ; Jung JK; Lee OJ; Yun SJ; Kim WJ; Shin EY; Kim EG
Oncogene; 2018 Sep; 37(38):5147-5159. PubMed ID: 29849120
[TBL] [Abstract] [Full Text] [Related]
9. Treatment strategy for metastatic prostate cancer with extremely high PSA level: reconsidering the value of vintage therapy.
Yamada Y; Sakamoto S; Amiya Y; Sasaki M; Shima T; Komiya A; Suzuki N; Akakura K; Ichikawa T; Nakatsu H
Asian J Androl; 2018; 20(5):432-437. PubMed ID: 29735818
[TBL] [Abstract] [Full Text] [Related]
10. ITGB1-dependent upregulation of Caveolin-1 switches TGFβ signalling from tumour-suppressive to oncogenic in prostate cancer.
Pellinen T; Blom S; Sánchez S; Välimäki K; Mpindi JP; Azegrouz H; Strippoli R; Nieto R; Vitón M; Palacios I; Turkki R; Wang Y; Sánchez-Alvarez M; Nordling S; Bützow A; Mirtti T; Rannikko A; Montoya MC; Kallioniemi O; Del Pozo MA
Sci Rep; 2018 Feb; 8(1):2338. PubMed ID: 29402961
[TBL] [Abstract] [Full Text] [Related]
11. Identifying global expression patterns and key regulators in epithelial to mesenchymal transition through multi-study integration.
Parsana P; Amend SR; Hernandez J; Pienta KJ; Battle A
BMC Cancer; 2017 Jun; 17(1):447. PubMed ID: 28651527
[TBL] [Abstract] [Full Text] [Related]
12. DNA methylation variations are required for epithelial-to-mesenchymal transition induced by cancer-associated fibroblasts in prostate cancer cells.
Pistore C; Giannoni E; Colangelo T; Rizzo F; Magnani E; Muccillo L; Giurato G; Mancini M; Rizzo S; Riccardi M; Sahnane N; Del Vescovo V; Kishore K; Mandruzzato M; Macchi F; Pelizzola M; Denti MA; Furlan D; Weisz A; Colantuoni V; Chiarugi P; Bonapace IM
Oncogene; 2017 Oct; 36(40):5551-5566. PubMed ID: 28581528
[TBL] [Abstract] [Full Text] [Related]
13. Development and internal validation of a multivariable prediction model for biochemical failure after whole-gland salvage iodine-125 prostate brachytherapy for recurrent prostate cancer.
Peters M; van der Voort van Zyp JRN; Moerland MA; Hoekstra CJ; van de Pol S; Westendorp H; Maenhout M; Kattevilder R; Verkooijen HM; van Rossum PSN; Ahmed HU; Shah TT; Emberton M; van Vulpen M
Brachytherapy; 2016; 15(3):296-305. PubMed ID: 26948662
[TBL] [Abstract] [Full Text] [Related]
14. cancer survival in Cali, Colombia: A population-based study, 1995-2004.
Bravo LE; García LS; Collazos PA
Colomb Med (Cali); 2014; 45(3):110-6. PubMed ID: 25386036
[TBL] [Abstract] [Full Text] [Related]
15. [Comparative analysis of gene expression in normal and cancer human prostate cell lines].
Rosenberg IeE; Herashchenko HV; Kashuba VI
Ukr Biochem J; 2014; 86(2):119-28. PubMed ID: 24868918
[TBL] [Abstract] [Full Text] [Related]
16. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
[TBL] [Abstract] [Full Text] [Related]
17. A search for reliable molecular markers of prognosis in prostate cancer: a study of 240 cases.
Tradonsky A; Rubin T; Beck R; Ring B; Seitz R; Mair S
Am J Clin Pathol; 2012 Jun; 137(6):918-30. PubMed ID: 22586051
[TBL] [Abstract] [Full Text] [Related]
18. Comprehensive genetic evaluation of common E-cadherin sequence variants and prostate cancer risk: strong confirmation of functional promoter SNP.
Lindström S; Wiklund F; Jonsson BA; Adami HO; Bälter K; Brookes AJ; Xu J; Zheng SL; Isaacs WB; Adolfsson J; Grönberg H
Hum Genet; 2005 Dec; 118(3-4):339-47. PubMed ID: 16189707
[TBL] [Abstract] [Full Text] [Related]
19. Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease.
Singal R; Ferdinand L; Reis IM; Schlesselman JJ
Oncol Rep; 2004 Sep; 12(3):631-7. PubMed ID: 15289848
[TBL] [Abstract] [Full Text] [Related]
20. Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation.
Padar A; Sathyanarayana UG; Suzuki M; Maruyama R; Hsieh JT; Frenkel EP; Minna JD; Gazdar AF
Clin Cancer Res; 2003 Oct; 9(13):4730-4. PubMed ID: 14581343
[TBL] [Abstract] [Full Text] [Related]
[Next]
